Prime Medicine Inc (NASDAQ: PRME) on Monday, soared 13.35% from the previous trading day, before settling in for the closing price of $3.37. Within the past 52 weeks, PRME’s price has moved between $1.11 and $6.94.
A company in the Healthcare sector has dropped its sales by -124.13% annually for the last half of the decade. The company achieved an average annual earnings per share of 19.70%. With a float of $93.82 million, this company’s outstanding shares have now reached $180.31 million.
Prime Medicine Inc (PRME) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Prime Medicine Inc is 48.03%, while institutional ownership is 38.10%. The most recent insider transaction that took place on Aug 01 ’25, was worth 4,950,000. In this transaction 10% Owner of this company bought 1,500,000 shares at a rate of $3.30, taking the stock ownership to the 3,262,440 shares. Before that another transaction happened on Aug 01 ’25, when Company’s Director bought 3,030,300 for $3.30, making the entire transaction worth $9,999,990. This insider now owns 6,230,300 shares in total.
Prime Medicine Inc (PRME) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.31 earnings per share (EPS) for the period topping the consensus outlook (set at -0.31) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.25 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 19.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.22% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Prime Medicine Inc (PRME) is currently performing well based on its current performance indicators. A quick ratio of 6.61 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 115.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.48, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -0.94 in one year’s time.
Technical Analysis of Prime Medicine Inc (PRME)
Let’s dig in a bit further. During the last 5-days, its volume was 4.99 million. That was better than the volume of 2.88 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 22.80%.
During the past 100 days, Prime Medicine Inc’s (PRME) raw stochastic average was set at 33.05%, which indicates a significant decrease from 35.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.42 in the past 14 days, which was lower than the 0.44 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.98, while its 200-day Moving Average is $3.11. However, in the short run, Prime Medicine Inc’s stock first resistance to watch stands at $3.98. Second resistance stands at $4.15. The third major resistance level sits at $4.47. If the price goes on to break the first support level at $3.49, it is likely to go to the next support level at $3.17. The third support level lies at $3.00 if the price breaches the second support level.
Prime Medicine Inc (NASDAQ: PRME) Key Stats
Market capitalization of the company is 689.55 million based on 180,511K outstanding shares. Right now, sales total 2,980 K and income totals -195,880 K. The company made 1,230 K in profit during its latest quarter, and -50,580 K in sales during its previous quarter.
